Fri Sep 20 08:08:45 UTC 2024: ## Moors & Cabot Increases Stake in SPDR S&P Biotech ETF (XBI)

**New York, NY – September 20, 2024** – Investment firm Moors & Cabot Inc. has increased its stake in the SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.4% during the second quarter, according to a recent SEC filing. The firm now owns 6,937 shares of the exchange-traded fund, valued at $643,000.

Moors & Cabot is not alone in its bullish stance on the biotech sector. Several other institutional investors and hedge funds have also purchased new positions in XBI in recent months, including ICA Group Wealth Management LLC, Scarborough Advisors LLC, BOCHK Asset Management Ltd, ORG Partners LLC, and Vima LLC.

The SPDR S&P Biotech ETF seeks to track the performance of the S&P Biotechnology Select Industry Index, which represents the biotechnology sub-sector of the broader S&P Total Markets Index. The fund has a market cap of $7.81 billion and has traded within a range of $63.80 to $103.52 over the past year.

**Shares of XBI opened at $102.43 on Friday.**

For investors interested in exploring further investment opportunities in the biotechnology sector, HoldingsChannel.com offers access to the latest 13F filings and insider trades for SPDR S&P Biotech ETF.

**To receive daily news and analyst ratings for SPDR S&P Biotech ETF and related companies, sign up for MarketBeat.com’s free daily email newsletter.**

Read More